2023 World Conference on Lung Cancer (Posters)-P1.21. Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI

P1.21. Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to identify potential biomarkers in serum glycoproteomics that could predict survival outcomes and immune-related adverse events (irAEs) in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) therapy. The researchers analyzed glycopeptides derived from serum proteins in pretreatment blood samples from a cohort of 61 NSCLC patients using liquid chromatography/mass spectrometry. They identified 20 biomarkers, including glycopeptides and non-glycosylated peptides, that were strongly associated with overall survival (OS) or selected in initial models. The abundance of these biomarkers was used to cluster patients into two groups. Group A, consisting of 51 patients, showed significantly inferior survival outcomes and progression-free survival (PFS) compared to group B. In patients who received an ICI-containing regimen, group A still demonstrated unfavorable OS and PFS. Additionally, 43% of patients developed irAEs, with 11% experiencing grade 3 irAEs. Group A showed a trend towards a shorter duration between ICI treatment initiation and the development of the first irAE of all grades. The authors concluded that patients clustered based on glycoproteomic signatures showed differences in survival outcomes and irAE development. Further validation is needed to develop a biomarker utilizing serum glycoproteomics to predict survival outcomes and irAE development in NSCLC patients treated with ICI therapy. This study highlights the potential of glycoproteomics as a promising approach for predicting treatment response and adverse events in NSCLC patients receiving immunotherapy.

Asset Subtitle

Young Kwang Chae

Meta Tag

Speaker Young Kwang Chae

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

serum glycoproteomics

biomarkers

survival outcomes

immune-related adverse events

non-small cell lung cancer

liquid chromatography/mass spectrometry

glycopeptides

overall survival

progression-free survival

immunotherapy